食品伙伴网讯  据欧盟食品安全局（EFSA）消息，继欧洲爆发马肉风波后，欧盟委员会要求欧盟食品安全局就马肉中的抗炎药苯基丁氮酮（保泰松）对人体的风险进行评估。

    在部分欧盟成员国，保泰松可作为缓解疼痛以及抗炎的药物用于狗、马等非产肉动物。欧盟严禁保泰松用于产肉动物，因此任何动物性食品检出该药物都是非法使用的结果。

    部分原文报道如下：

    The European Union agencies will provide scientific advice by 15 April 2013 to help inform decision-making of the European Commission with regard to these recent findings.

    In carrying out the joint risk assessment, the two agencies will use all available scientific evidence and consider data and results of ongoing testing of horsemeat in Member States as these become available.

    In a joint statement, EFSA and EMA will provide advice on any potential risk for consumers arising from the presence of phenylbutazone residues in horsemeat. In this regard, the agencies will consider both the risk posed from consumption of horsemeat itself as well as that arising from other products illegally contaminated with horsemeat. The agencies have been asked to advise, where appropriate, if additional control options are needed to minimise any risks identified.

    Phenylbutazone is used sparingly in human medicine for the treatment of severe inflammatory conditions where no other treatment is considered suitable. In veterinary medicine its use is permitted in some Member States for pain relief and to reduce inflammation in non-food producing animals （dogs, sport horses）。

    原文链接：<http://www.efsa.europa.eu/en/press/news/130307.htm>